Henk Doude van Troostwijk
Corporate Officer/Principal chez HANSA BIOPHARMA AB
Profil
Henk Doude van Troostwijk is currently the Chief Commercial Officer & Senior VP at Hansa Biopharma AB since 2019.
Prior to this, he worked as the Director-Oncology & Transplantation at Genzyme Europe BV, General Manager-European Commercial Operations at Raptor Pharmaceuticals Corp., and General Manager-European Commercial Operations at Horizon Pharmaceutical LLC.
He holds an MBA degree from Henley Management College.
Postes actifs de Henk Doude van Troostwijk
| Sociétés | Poste | Début |
|---|---|---|
| HANSA BIOPHARMA AB | Corporate Officer/Principal | 01/06/2019 |
Anciens postes connus de Henk Doude van Troostwijk
| Sociétés | Poste | Fin |
|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Corporate Officer/Principal | - |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Corporate Officer/Principal | - |
| RAPTOR PHARMACEUTICAL CORP | Corporate Officer/Principal | - |
Formation de Henk Doude van Troostwijk
| Henley Management College | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HANSA BIOPHARMA AB | Health Technology |
| Entreprise privées | 3 |
|---|---|
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
